Cancer bronchique non à petites cellules avec autres mutations actionnables (BRAF, MET, HER2)

Non-Small Cell Lung Cancer (NSCLC) outcomes has been significantly improved since the discovery of oncogenic driver alterations and implementation of targeted therapies such as tyrosine kinase inhibitors, antibody drug conjugates or bispecific antibodies. Nowadays, wild molecular profiling, preferably with next-generation sequencing panels is crucial before starting treatment in patients with non-squamous NSCLC regardless of their smoking status, and in those with squamous NSCLC who are little or non-smokers, on tissue samples but also liquid biopsies that can tremendously helpful despite their lack of sensitivity. In this review, we will present the latest evidence on some rare molecular alterations, BRAF, MET and HER2, with constant innovation pipeline. Even if many of these new drugs are still not funded in Europe, clinical trials enrollment allows our patients to benefit from innovative treatments and generate data. Translational research programs with repeat samples are also important to explore mechanisms of resistance to these new drugs.